│Home│Sitemap│Notes for Usage│Inquiry│日本語│

May 25, 2016 Signed Agreement with Surgical Oncology in Nagoya University on "Development and Clinical Apply of Drug Delivery System on Nek2 siRNA Nucleic Acid Drug" May 25, 2016 3 Years Government Grant, Nucleic Acid Liposome Project with Research Institute for Microbial Diseases in Osaka University got AMED Grant Oct 20, 2015 Mebiopharm Announces Technology Evaluation Agreement with Merck to explore new tumor specific formulations May 29, 2015 MBP-Y003 MOU executed MOU execution with Fuan Pharmaceutical (Group) Co., Ltd. to license out the right to develop and commercialize for MBP-Y003, liposomal product attached transferrin as a ligand encapsulating Methotrexate, in China territory. USD 1,000,000 as an upfront payment Jun 07, 2013 Announcement of Delisting and Arrangement of Shares May 31, 2013 Venturing into the Japanese investment market with Mebiopharm Scrip Intelligence Online (May 30th) Feb 12, 2013 Announcement of Developing Contrast Agent Using Nano-particle for Ultrasound Contrast Oct 18, 2012 Presentation at 2nd APSTJ Meeting of DDS Focus Group on October 28, 2012 (Link in Japanese) Sep 01, 2012 Presentation at 4th Annual Partnerships in Clinical Trials(Shanghai) on September 13, 2012 Jun 01, 2012 Starting a Clinical Study for Pancreatic Cancer Mar 21, 2012 Presentation at Drug Discovery & Development Japan (Tokyo) on June 13, 2012 Feb 27, 2012 Consulting Agreement with Dr. Jean-Pierre Armand, M.D., MS.c, a world authority on cancer research field and a heavyweight in medical community in the world, for Mebiopharm's Phase 2 clinical trial in Europe. Feb 20, 2012 Joint Venture Establishment in Sri Lanka Feb 13, 2012 Presentation at Clinical Trials and Outsourcing (Shanghai) Dec 07, 2011 Joint press conference on a joint venture in Sri Lanka (pdf in Japanese) Dec 07, 2011 Announcement of establishing a joint venture in Sri Lanka (pdf in Japanese) Nov 11, 2011 Lecture in 2nd Tokyo Venture Forum at Tokyo Stock Exchange Oct 21, 2011 Presentation at JVCA (Japan Venture Capital Association) Oct 12, 2011 Presentation about "Partnering with Japan for Clinical Trials" in Clinical Trials Asia Japan 2011 (Shanghai) Sep 16, 2011 IR briefing session at Phillip Securities (HK) Ltd. Branch (Hong Kong, North Point) Jul 15, 2011 Announcement of the listing on TOKYO AIM Jul 11, 2011 Basic agreement about Technology Transfer between Chinese Pharma (in Japanese) Jun 10, 2011 Investor Relations updated. (in Japanese) Nov 10, 2010 Presentation by Dr. Jaffer Ajani (Prof. MDAnderson Cancer Center) about of MBP-426 Phase 2 study in PSWC 2010 in New Orleans (14-18 Nov.2010). Sep 6, 2010 Article in NIKKEI newspaper about business collaboration with Chinese Pharma for licensing development right in Chinese market. Aug 11, 2010 300million yen was invested through a private equity placement. Aug 10, 2010 Presentation on September 29 about Clinical Development of Anticancer Drug in BioJapan2010. Aug 1, 2010 "A study and development of evaluation methods of formulation and production to build up a scientific development strategy for drug formulation and production" by National Institute of Health Science that Mebiopharm takes part, is adopted as the governmental program "Health and Labour Sciences Research Grants / Research on Publicly Essential Drugs and Medical Devices". Jul 15, 2010 Article about MBP-426 in Nikkei Sangyo Shinbun Link (only in Japanese) May 18, 2010 Presentation at the annual meeting of The Japan Society of Drug Delivery System Link (only in Japanese) Nov 18, 2009 Presentation on Phase 1b Study result of MBP-426 at the AACR-NCI-EORTC International Conference in Boston Link to the poster Sep 10, 2009 Presentation in Japan Biotech Forum in London 2009 Link to the website May 30, 2009 MBP-426 promising Phase I result to be presented at ASCO 2009 Link to the poster Feb 04, 2009 Phase II trial for 2nd line Gastric plus GE junction starts in U.S Nikkei Biotech online 　 　 ◆ Click here to see past articles